Could a drug boost radiation for prostate cancer?

NCT ID NCT03795207

First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 4 times

Summary

This study tests whether adding the drug durvalumab to targeted radiation therapy helps control prostate cancer that has come back in a few spots (up to 5). About 96 men with hormone-sensitive prostate cancer will receive either radiation alone or radiation plus durvalumab for 12 months. The goal is to see if the combination delays cancer progression better than radiation alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHRU de Brest

    Brest, 29200, France

  • Centre Georges François Leclerc

    Dijon, 21079, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Chbs Lorient

    Lorient, 56100, France

  • Hospices Civils de Lyon

    Pierre-Bénite, 69310, France

  • ICO

    Saint-Herblain, 44805, France

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut de Cancérologie de Montpellier

    Montpellier, 34298, France

Conditions

Explore the condition pages connected to this study.